Peking University is conducting a multicenter study looking at the impact of using high-dose dexamethasone, a corticosteroid, in combination with a drug called Teriflunomide which is an immune modulator thought to work by decreasing inflammation and decreasing the action of immune cells in the treatment of newly diagnosed primary ITP. Eligible participants include adults between 18-80 years who have never been treated for their newly diagnosed ITP and have a platelet count less than 30,000 or less than 50,000 with bleeding symptoms that require treatment.
China
Actively Recruiting